 EMERYVILLE, Calif., May 27, 2021 PRNewswire -- Dynavax Technologies Corporation Nasdaq: DVAX, a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B Hepatitis B Vaccine Recombinant, Adjuvanted in Germany with an expected launch in the fourth quarter of 2021. 